Michelle Nottage

2.4k total citations
19 papers, 236 citations indexed

About

Michelle Nottage is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Michelle Nottage has authored 19 papers receiving a total of 236 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Epidemiology. Recurrent topics in Michelle Nottage's work include HER2/EGFR in Cancer Research (5 papers), Nonmelanoma Skin Cancer Studies (5 papers) and Advanced Breast Cancer Therapies (4 papers). Michelle Nottage is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Nonmelanoma Skin Cancer Studies (5 papers) and Advanced Breast Cancer Therapies (4 papers). Michelle Nottage collaborates with scholars based in Australia, Canada and United States. Michelle Nottage's co-authors include Lillian L. Siu, Brett Hughes, Liz Kenny, Charles Lin, David Smith, Anjela Tzontcheva, Gregory R. Pond, Irene L. Andrulis, Shelley B. Bull and Karen Kopciuk and has published in prestigious journals such as Journal of Clinical Oncology, Breast Cancer Research and Treatment and Breast Cancer Research.

In The Last Decade

Michelle Nottage

18 papers receiving 228 citations

Peers

Michelle Nottage
Sandra S. Zaky United States
María Jesús Quintana Spain
Jiannan Wu China
Romana Idress Pakistan
Haocan Song United States
Fredrika Killander Sweden
Aaron E. Sosa Spain
Kilian Salerno May United States
Phil Jo Choi South Korea
Ronald Arpin United States
Sandra S. Zaky United States
Michelle Nottage
Citations per year, relative to Michelle Nottage Michelle Nottage (= 1×) peers Sandra S. Zaky

Countries citing papers authored by Michelle Nottage

Since Specialization
Citations

This map shows the geographic impact of Michelle Nottage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Nottage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Nottage more than expected).

Fields of papers citing papers by Michelle Nottage

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Nottage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Nottage. The network helps show where Michelle Nottage may publish in the future.

Co-authorship network of co-authors of Michelle Nottage

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Nottage. A scholar is included among the top collaborators of Michelle Nottage based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Nottage. Michelle Nottage is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Ladwa, Rahul, Jenny Lee, Caroline Cooper, et al.. (2025). Response-Adapted Surgical and Radiotherapy De-Escalation in Resectable Cutaneous Squamous Cell Cancer Using Pembrolizumab: The De-Squamate Study. Journal of Clinical Oncology. 43(26). 2888–2896. 1 indexed citations
2.
Ladwa, Rahul, Jenny Lee, Sandro Porceddu, et al.. (2024). A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma (cSCC) with the use of neoadjuvant pembrolizumab: De-Squamate.. Journal of Clinical Oncology. 42(16_suppl). 9514–9514. 7 indexed citations
3.
Lok, Sheau Wen, Richard de Boer, Laeeq Malik, et al.. (2023). Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer. Breast Cancer Research and Treatment. 198(1). 67–74. 7 indexed citations
4.
Lok, Sheau Wen, A. Antón, Sally Baron‐Hay, et al.. (2023). Real world evidence of systemic therapy in hormone receptor positive advanced breast cancer (HR+ ABC) in Australia: ARORA Registry.. Journal of Clinical Oncology. 41(16_suppl). e13054–e13054. 1 indexed citations
5.
Wong, Vanessa, Richard de Boer, Sally Baron‐Hay, et al.. (2022). Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer. Clinical Breast Cancer. 22(8). 792–800. 7 indexed citations
6.
Wong, Vanessa, Richard de Boer, Belinda Yeo, et al.. (2022). Real-World Outcomes in Patients With Brain Metastases Secondary to HER2-Positive Breast Cancer: An Australian Multi-centre Registry-based Study. Clinical Breast Cancer. 22(7). e764–e772. 1 indexed citations
7.
8.
9.
Nottage, Michelle, et al.. (2021). Assessing the accuracy of 68Ga‐PSMA PET/CT compared with MRI in the initial diagnosis of prostate malignancy: A cohort analysis of 114 consecutive patients. Journal of Medical Imaging and Radiation Oncology. 66(3). 319–323. 3 indexed citations
10.
Kanjanapan, Yada, Sheau Wen Lok, Peter Gibbs, et al.. (2020). Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer. Breast Cancer Research and Treatment. 184(1). 87–95. 3 indexed citations
11.
Boer, Richard H. De, Sheau Wen Lok, Peter Gibbs, et al.. (2020). Real‐world impact of anti‐HER2 therapy‐related cardiotoxicity in patients with advanced HER2‐positive breast cancer. Asia-Pacific Journal of Clinical Oncology. 16(6). 356–362. 2 indexed citations
12.
Leung, John, Dylan Bartholomeusz, Peter Sutherland, et al.. (2018). Comparative study between 68Ga‐prostate‐specific membrane antigen positron emission tomography and conventional imaging in the initial staging of prostate cancer. Journal of Medical Imaging and Radiation Oncology. 62(6). 816–822. 21 indexed citations
13.
Nottage, Michelle, et al.. (2016). Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin. Head & Neck. 39(4). 679–683. 46 indexed citations
14.
Nottage, Michelle, et al.. (2012). A prospective study investigating the impact of definitive chemoradiation in locoregionally advanced squamous cell carcinoma of the skin.. Journal of Clinical Oncology. 30(15_suppl). 8538–8538. 3 indexed citations
15.
Nottage, Michelle, Karen Kopciuk, Anjela Tzontcheva, et al.. (2006). Analysis of incidence and prognostic factors for ipsilateral breast tumour recurrence and its impact on disease-specific survival of women with node-negative breast cancer: a prospective cohort study. Breast Cancer Research. 8(4). R44–R44. 30 indexed citations
16.
Durán, Ignacio, Lillian L. Siu, Eric X. Chen, et al.. (2005). Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors. Anti-Cancer Drugs. 17(1). 81–87. 3 indexed citations
17.
Nottage, Michelle, Sue‐Anne McLachlan, Amit M. Oza, et al.. (2003). Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Supportive Care in Cancer. 11(1). 41–47. 40 indexed citations
18.
Nottage, Michelle & Lillian L. Siu. (2002). Principles of clinical trial design.. PubMed. 20(18 Suppl). 42S–6S. 23 indexed citations
19.
Nottage, Michelle & Lillian L. Siu. (2002). Rationale for Ras and Raf-kinase as a Target for Cancer Therapeutics. Current Pharmaceutical Design. 8(25). 2231–2242. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sandra S. Zaky Breakdown of academic impact, for papers by María Jesús Quintana Breakdown of academic impact, for papers by Jiannan Wu Breakdown of academic impact, for papers by Romana Idress Breakdown of academic impact, for papers by Haocan Song Breakdown of academic impact, for papers by Fredrika Killander Breakdown of academic impact, for papers by Aaron E. Sosa Breakdown of academic impact, for papers by Kilian Salerno May Breakdown of academic impact, for papers by Phil Jo Choi Breakdown of academic impact, for papers by Ronald Arpin
Rankless by CCL
2026